Total Payments
$276,181
2024 Payments
$5,987
Companies
7
Transactions
25
Medicare Patients
1,024
Medicare Billing
$144,323
Payment Breakdown by Category
Research$275,775 (99.9%)
Food & Beverage$406.31 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $275,775 | 18 | 99.9% |
| Food and Beverage | $406.31 | 7 | 0.1% |
Payments by Type
Research
$275,775
18 transactions
General
$406.31
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $180,539 | 7 | $0 (2024) |
| Janssen Research & Development, LLC | $95,237 | 11 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $127.83 | 1 | $0 (2022) |
| Abbott Laboratories | $115.09 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $113.66 | 2 | $0 (2020) |
| PFIZER INC. | $35.05 | 2 | $0 (2023) |
| Cranial Technologies, Inc | $14.68 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,987 | 2 | Janssen Research & Development, LLC ($3,478) |
| 2023 | $13,523 | 7 | Janssen Research & Development, LLC ($12,501) |
| 2022 | $79,836 | 9 | Janssen Research & Development, LLC ($79,258) |
| 2021 | $176,576 | 2 | Eli Lilly and Company ($176,576) |
| 2020 | $130.27 | 3 | Janssen Pharmaceuticals, Inc ($113.66) |
| 2018 | $129.77 | 2 | Abbott Laboratories ($115.09) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,509.00 | Research |
| Study: AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | ||||||
| 03/31/2024 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $3,477.50 | Research |
| Study: 42847922ALZ2001 | ||||||
| 12/31/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $3,302.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 09/30/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $3,302.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 06/30/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $5,897.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 05/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $400.00 | Research |
| Study: AN ADAPTIVE PHASE 2A/2B RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | ||||||
| 05/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $303.08 | Research |
| Study: ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 05/04/2023 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 12/22/2022 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $4,431.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 11/17/2022 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $3,160.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 10/13/2022 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $5,897.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 09/15/2022 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $18,483.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 09/01/2022 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | In-kind items and services | $127.83 | General |
| Category: Cardiovascular | ||||||
| 08/25/2022 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $7,725.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 08/11/2022 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $14,560.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 08/04/2022 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $25,002.00 | Research |
| Study: 42847922ALZ2001 | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $450.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 07/20/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $163,252.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 04/13/2021 | Eli Lilly and Company | — | — | In-kind items and services | $13,324.47 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 03/06/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $105.35 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/06/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $8.31 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/20/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/27/2018 | Abbott Laboratories | No Associated Product (Device) | Food and Beverage | In-kind items and services | $115.09 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 05/29/2018 | Cranial Technologies, Inc | Doc Band (Device) | Food and Beverage | Cash or cash equivalent | $14.68 | General |
| Category: Cranial Orthotic | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $177,026 | 3 |
| 42847922ALZ2001 | Janssen Research & Development, LLC | $95,237 | 11 |
| AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | Eli Lilly and Company | $2,509 | 1 |
| AN ADAPTIVE PHASE 2A/2B RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | Eli Lilly and Company | $400.00 | 1 |
| ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $303.08 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 239 | 495 | $55,661 | $37,121 |
| 2022 | 8 | 286 | 499 | $60,549 | $36,674 |
| 2021 | 6 | 213 | 368 | $46,262 | $29,387 |
| 2020 | 7 | 286 | 545 | $65,791 | $41,141 |
Total Patients
1,024
Total Services
1,907
Medicare Billing
$144,323
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 65 | 281 | $26,827 | $18,987 | 70.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 54 | 56 | $10,494 | $6,278 | 59.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 76 | 80 | $7,727 | $5,486 | 71.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 30 | $8,070 | $4,375 | 54.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 48 | $2,544 | $1,994 | 78.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 51 | 237 | $22,778 | $14,363 | 63.1% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 46 | 48 | $11,760 | $6,886 | 58.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 39 | 39 | $7,383 | $4,044 | 54.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 53 | 54 | $5,257 | $3,243 | 61.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $4,842 | $2,820 | 58.2% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 43 | 44 | $4,268 | $2,624 | 61.5% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 21 | 27 | $2,565 | $1,607 | 62.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 32 | $1,696 | $1,088 | 64.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 55 | 204 | $19,380 | $12,411 | 64.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 41 | 42 | $7,686 | $4,851 | 63.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 57 | 61 | $5,795 | $3,802 | 65.6% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2021 | 25 | 25 | $6,125 | $3,785 | 61.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 21 | 22 | $5,918 | $3,665 | 61.9% |
| 99217 | Hospital observation care on day of discharge | Facility | 2021 | 14 | 14 | $1,358 | $872.62 | 64.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 66 | 289 | $27,981 | $17,714 | 63.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 40 | 41 | $11,742 | $6,987 | 59.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 46 | 47 | $8,601 | $5,384 | 62.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 78 | 83 | $8,138 | $5,074 | 62.3% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2020 | 21 | 21 | $5,145 | $3,254 | 63.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 17 | 46 | $2,438 | $1,589 | 65.2% |
About Dr. Adolfo Cueli, M.D
Dr. Adolfo Cueli, M.D is a Family Medicine healthcare provider based in Homestead, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1710148499.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adolfo Cueli, M.D has received a total of $276,181 in payments from pharmaceutical and medical device companies, with $5,987 received in 2024. These payments were reported across 25 transactions from 7 companies. The most common payment nature is "" ($275,775).
As a Medicare-enrolled provider, Cueli has provided services to 1,024 Medicare beneficiaries, totaling 1,907 services with total Medicare billing of $144,323. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Other Specialties Student in an Organized Health Care Education/Training Program
- Location Homestead, FL
- Active Since 06/24/2008
- Last Updated 05/23/2019
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1710148499
Products in Payments
- Optimizer (Device) $127.83
- No Associated Product (Device) $115.09
- XARELTO (Drug) $113.66
- ELIQUIS (Drug) $35.05
- Doc Band (Device) $14.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Homestead
Dr. Roberto Bermudez, Md, MD
Family Medicine — Payments: $13,654
Family Medicine $13,654
Dr. Luisa Lopez-Luciano, M.d, M.D
Family Medicine — Payments: $12,791
Family Medicine $12,791
Dr. Josefa Binker, Md, MD
Family Medicine — Payments: $8,456
Family Medicine $8,456
Mark Rosenthal, D.o, D.O
Family Medicine — Payments: $6,544
Family Medicine $6,544
Mariela Perez, Md, MD
Family Medicine — Payments: $6,415
Family Medicine $6,415
Dr. Abid Chaudhry, M.d, M.D
Family Medicine — Payments: $3,611
Family Medicine $3,611